Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 595.00Impact Factor 2024: 3.4
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease.
The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease.
Authors: Ferro, Doeschka A. | van Veluw, Susanne J. | Koek, Huiberdina L. | Exalto, Lieza G. | Biessels, Geert Jan | on behalf of the Utrecht Vascular Cognitive Impairment (VCI) study group
Article Type: Research Article
Abstract: Background: Cerebral microinfarcts (CMIs) are small ischemic lesions that are a common neuropathological finding in patients with stroke or dementia. CMIs in the cortex can now be detected in vivo on 3 Tesla MRI. Objective: To determine the occurrence of CMIs and associated clinical features in patients with possible vascular cognitive impairment (VCI). Method: 182 memory-clinic patients (mean age 71.4±10.6, 55% male) with vascular injury on brain MRI (i.e., possible VCI) underwent a standardized work-up including 3 Tesla MRI and cognitive assessment. A control group consisted of 70 cognitively normal subjects (mean age 70.6±4.7, 60% …male). Cortical CMIs and other neuroimaging markers of vascular brain injury were rated according to established criteria. Result: Occurrence of CMIs was higher (20%) in patients compared to controls (10%). Among patients, the presence of CMIs was associated with male sex, history of stroke, infarcts, and white matter hyperintensities. CMI presence was also associated with a diagnosis of vascular dementia and reduced performance in multiple cognitive domains. Conclusion: CMIs on 3 Tesla MRI are common in patients with possible VCI and co-occur with imaging markers of small and large vessel disease, likely reflecting a heterogeneous etiology. CMIs are associated with worse cognitive performance, independent of other markers of vascular brain injury. Show more
Keywords: Cerebral small vessel disease, cerebrovascular disease, dementia, infarct, magnetic resonance imaging, neuropsychological test
DOI: 10.3233/JAD-170481
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1443-1450, 2017
Authors: Dumurgier, Julien | Hanseeuw, Bernard J. | Hatling, Frances B. | Judge, Kelly A. | Schultz, Aaron P. | Chhatwal, Jasmeer P. | Blacker, Deborah | Sperling, Reisa A. | Johnson, Keith A. | Hyman, Bradley T. | Gómez-Isla, Teresa
Article Type: Research Article
Abstract: Background: Identifying older adults at risk of cognitive decline represents a challenge as Alzheimer’s disease (AD) modifying therapies move toward preclinical stages. Objective: To investigate the relationship between AD biomarkers and subsequent change in cognition in a cohort of cognitively intact older adults. Methods: 84 cognitively normal subjects (mean age 72.0 years, 59% women) were recruited through the Massachusetts Alzheimer’s Disease Research Center and the Harvard Aging Brain Study and followed over 3 years. Measurements of amyloid-β 1–42 (Aβ42 ), total Tau (t-Tau), and Tau phosphorylated at threonine 181 (p-Tau181) in the cerebrospinal fluid (CSF) at …study entry were available in all cases. Baseline brain MRI, FDG-PET, and PiB-PET data were available in the majority of participants. Relationship between baseline AD biomarkers and longitudinal change in cognition was assessed using Cox proportional hazard regression and linear mixed models. Results: 14% participants increased their global Clinical Dementia Rating (CDR) score from 0 to 0.5 during follow-up. A CDR score increase was associated with higher baseline CSF t-Tau and p-Tau181, higher global cortical PiB retention, and lower hippocampal volume. The combination of high CSF t-Tau and low Aβ42 or low hippocampal volume was more strongly related to cognitive outcome than each single biomarker. Higher CSF t-Tau was the only biomarker associated with subsequent decline in MMSE score. Conclusions: Baseline CSF t-Tau and p-Tau181, in vivo amyloid load, and hippocampal volume were all independently associated with future decline in cognition. The discriminatory ability of these biomarkers to predict risk of cognitive decline, however, was only modest. Show more
Keywords: Biomarkers, cognitive decline, cerebrospinal fluid, epidemiology, neuroimaging
DOI: 10.3233/JAD-170511
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1451-1459, 2017
Authors: Yordanova, Kristina | Koldrack, Philipp | Heine, Christina | Henkel, Ron | Martin, Mike | Teipel, Stefan | Kirste, Thomas
Article Type: Research Article
Abstract: Background: Dementia impairs spatial orientation and route planning, thus often affecting the patient’s ability to move outdoors and maintain social activities. Situation-aware deliberative assistive technology devices (ATD) can substitute impaired cognitive function in order to maintain one’s level of social activity. To build such a system, one needs domain knowledge about the patient’s situation and needs. We call this collection of knowledge situation model. Objective: To construct a situation model for the outdoor mobility of people with dementia (PwD). The model serves two purposes: 1) as a knowledge base from which to build an ATD describing the mobility …of PwD; and 2) as a codebook for the annotation of the recorded behavior. Methods: We perform systematic knowledge elicitation to obtain the relevant knowledge. The OBO Edit tool is used for implementing and validating the situation model. The model is evaluated by using it as a codebook for annotating the behavior of PwD during a mobility study and interrater agreement is computed. In addition, clinical experts perform manual evaluation and curation of the model. Results: The situation model consists of 101 concepts with 11 relation types between them. The results from the annotation showed substantial overlapping between two annotators (Cohen’s kappa of 0.61). Conclusion: The situation model is a first attempt to systematically collect and organize information related to the outdoor mobility of PwD for the purposes of situation-aware assistance. The model is the base for building an ATD able to provide situation-aware assistance and to potentially improve the quality of life of PwD. Show more
Keywords: Alzheimer’s disease, assistance, data collection, dementia, knowledge base, mobility limitation, situationawareness
DOI: 10.3233/JAD-170105
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1461-1476, 2017
Authors: Handels, Ron L.H. | Wimo, Anders | Dodel, Richard | Kramberger, Milica G. | Visser, Pieter Jelle | Molinuevo, José Luis | Verhey, Frans R.J. | Winblad, Bengt
Article Type: Research Article
Abstract: Background: Diagnostic research criteria for Alzheimer’s disease support the use of biomarkers in the cerebrospinal fluid (CSF) to improve the accuracy of the prognosis regarding progression to dementia for people with mild cognitive impairment (MCI). Objective: The aim of this study was to estimate the potential incremental cost-effectiveness ratio of adding CSF biomarker testing to the standard diagnostic workup to determine the prognosis for patients with MCI. Methods: In an early technology assessment, a mathematical simulation model was built, using available evidence on added prognostic value as well as expert opinion to estimate the incremental costs …and quality-adjusted life years (QALYs) of 20,000 virtual MCI patients with (intervention strategy) and without (control strategy) relying on CSF, from a health-care sector perspective and with a 5-year time horizon. Results: Adding the CSF test improved the accuracy of prognosis by 11%. This resulted in an average QALY gain of 0.046 and € 432 additional costs per patient, representing an incremental cost-effectiveness ratio of € 9,416. Conclusion: The results show the potential of CSF biomarkers in current practice from a health-economics perspective. This result was, however, marked by a high degree of uncertainty, and empirical research is required into the impact of a prognosis on worrying, false-positive/negative prognosis, and stigmatization. Show more
Keywords: Alzheimer’s disease, cerebrospinal fluid, cost-utility, economic evaluation, mild cognitive impairment, prognosis, risk
DOI: 10.3233/JAD-170324
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1477-1487, 2017
Authors: Sejunaite, Karolina | Lanza, Claudia | Riepe, Matthias W.
Article Type: Research Article
Abstract: Background: Errors of omission are an established hallmark of memory impairment in Alzheimer’s disease (AD). Much less is known about other memory errors in AD such as false memories. Objective: We investigated false memories in healthy elderly controls (HC; n = 23) and patients with AD (n = 20) using real-life tasks of watching news and commercials. Methods: Participants received a comprehensive neuropsychological assessment and were shown original news and commercials with a subsequent recognition task to assess veridical and false memories. Results: Subjective estimate of the number of errors were alike in HC and patients …with AD. However, memory performance in both the news and the commercials task was significantly worse in patients with AD. Trail-Making Test and Symbol-Span Test were significant predictors of false memories on viewing news and commercials. In patients with AD, levels of Aβ1 - 42 , but not levels of tau-protein were correlated with false memories in both tasks. Conclusions: Everyday life in patients with AD is impeded not due to the incompleteness of memory but also due to its distortions. Furthermore, it is hindered by the lack of awareness towards these deficits. False memory content in patients with AD is associated with Aβ42 levels in the CSF as a surrogate of the overall extent to which the brain has been affected by AD pathology. Future studies will need to address the impact of this duality of memory failure on everyday life of patients with AD and their proxies in greater detail. Show more
Keywords: Alzheimer’s disease, cerebrospinal fluid markers, episodic memory, everyday life, false memories, memory disorders, neuropsychology
DOI: 10.3233/JAD-170493
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1489-1498, 2017
Authors: Stelmokas, Julija | Yassay, Lance | Giordani, Bruno | Dodge, Hiroko H. | Dinov, Ivo D. | Bhaumik, Arijit | Sathian, K. | Hampstead, Benjamin M.
Article Type: Research Article
Abstract: NeuroQuant (NQ) is a fully-automated program that overcomes several existing limitations in the clinical translation of MRI-derived volumetry. The current study characterized differences between the original (NQ1) and an updated NQ version (NQ2) by 1) replicating previously identified relationships between neuropsychological test performance and medial temporal lobe volumes, 2) evaluating the level of agreement between NQ versions, and 3) determining if the addition of NQ2 age-/sex-based z-scores hold greater clinical utility for prediction of memory impairment than standard percent of intracranial volume (% ICV) values. Sixty-seven healthy older adults and 65 mild cognitive impairment patients underwent structural MRI and completed …cognitive testing, including the Immediate and Delayed Memory indices from the Repeatable Battery for the Assessment of Neuropsychological Status. Results generally replicated previous relationships between key medial temporal lobe regions and memory test performance, though comparison of NQ regions revealed statistically different values that were biased toward one version or the other depending on the region. NQ2 hippocampal z-scores explained additional variance in memory performance relative to % ICV values. Findings indicate that NQ1/2 medial temporal lobe volumes, especially age- and sex-based z-scores, hold clinical value, though caution is warranted when directly comparing volumes across NQ versions. Show more
Keywords: Alzheimer’s disease, amygdala, hippocampus, memory, neuroimaging
DOI: 10.3233/JAD-170306
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1499-1510, 2017
Authors: Hares, Kelly | Miners, James Scott | Cook, Amelia Jane | Rice, Claire | Scolding, Neil | Love, Seth | Wilkins, Alastair
Article Type: Research Article
Abstract: Defects in motor protein-mediated neuronal transport mechanisms have been implicated in a number of neurodegenerative disorders but remain relatively little studied in Alzheimer’s disease (AD). Our aim in the present study was to assess the expression of the anterograde kinesin superfamily motor proteins KIF5A, KIF1B, and KIF21B, and to examine their relationship to levels of hyperphosphorylated tau, amyloid-β protein precursor (AβPP), and amyloid-β (Aβ) in human brain tissue. We used a combination of qPCR, immunoblotting, and ELISA to perform these analyses in midfrontal cortex from 49 AD and 46 control brains. Expression of KIF5A, KIF1B, and KIF21B at gene and …protein level was significantly increased in AD. KIF5A protein expression correlated inversely with the levels of AβPP and soluble Aβ in AD brains. Upregulation of KIFs may be an adaptive response to impaired axonal transport in AD. Show more
Keywords: Alzheimer’s disease, amyloid, kinesin, tau
DOI: 10.3233/JAD-170094
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1511-1524, 2017
Authors: Devanand, D.P. | Lentz, Cody | Chunga, Richard E. | Ciarleglio, Adam | Scodes, Jennifer M. | Andrews, Howard | Schofield, Peter W. | Stern, Yaakov | Huey, Edward D. | Bell, Karen | Pelton, Gregory H.
Article Type: Research Article
Abstract: Background: Anticholinergic challenge can induce odor identification impairment that indicates Alzheimer’s disease pathology. Objective: To determine if decline in odor identification ability with anticholinergic challenge can predict improvement with donepezil, a cholinesterase inhibitor (ChEI), in patients with mild cognitive impairment (MCI). Methods: At baseline, the University of Pennsylvania Smell identification Test (UPSIT) was administered before and after an anticholinergic atropine nasal spray challenge. Donepezil was started at 5 mg daily, increased to 10 mg daily if tolerated, and then the dose was kept constant for 52 weeks. Main outcomes were change in Selective Reminding Test (SRT) total immediate …recall and ADAS-Cog total score from baseline to 26 and 52 weeks. Results: In 37 participants, mean age 70.4 (SD 9.8) y, greater atropine-induced decrease in UPSIT score at baseline was associated with greater improvement in SRT total recall score from baseline to 26 and 52 weeks (p < 0.03). This effect remained after adjusting for time, age, education, gender, APOE ɛ 4 status, and baseline cognitive score (p < 0.05). Decrease in UPSIT score was associated with global improvement (CIBIC-plus) over 52 weeks (p < 0.02). After excluding patients with congential anosmia, increase in UPSIT score from 0 to 8 weeks showed a trend-level association with improvement on the ADAS-Cog (p = 0.07). Conclusions: Anticholinergic challenge-induced odor identification decline was associated with cognitive improvement, and short-term improvement in odor identification tended to predict longer term cognitive improvement. These simple inexpensive strategies have the potential to improve selection of patients with MCI for ChEI treatment. Show more
Keywords: Acetylcholine, Alzheimer’s disease, mild cognitive impairment, olfaction
DOI: 10.3233/JAD-170497
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1525-1531, 2017
Authors: van Duijn, Sara | Bulk, Marjolein | van Duinen, Sjoerd G. | Nabuurs, Rob J.A. | van Buchem, Mark A. | van der Weerd, Louise | Natté, Remco
Article Type: Research Article
Abstract: Abnormal iron distribution in the isocortex is increasingly recognized as an in vivo marker for Alzheimer’s disease (AD). However, the contribution of iron accumulation to the AD pathology is still poorly understood. In this study, we investigated: 1) frontal cortical iron distribution in AD and normal aging and 2) the relation between iron distribution and degree of AD pathology. We used formalin fixed paraffin embedded frontal cortex from 10 AD patients, 10 elder, 10 middle aged, and 10 young controls and visualized iron with a modified Perl’s histochemical procedure. AD and elderly subjects were not different with respect to …age and sex distribution. Iron distribution in the frontal cortex was not affected by normal aging but was clearly different between AD and controls. AD showed accumulation of iron in plaques, activated microglia, and, in the most severe cases, in the mid-cortical layers along myelinated fibers. The degree of altered iron accumulations was correlated to the amount of amyloid-β plaques and tau pathology in the same block, as well as to Braak stage (p < 0.001). AD and normal aging show different iron and myelin distribution in frontal cortex. These changes appear to occur after the development of the AD pathological hallmarks. These findings may help the interpretation of high resolution in vivo MRI and suggest the potential of using changes in iron-based MRI contrast to indirectly determine the degree of AD pathology in the frontal cortex. Show more
Keywords: Alzheimer’s disease, iron, magnetic resonance imaging, myelin
DOI: 10.3233/JAD-161143
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1533-1545, 2017
Authors: André, Séverine | Ansciaux, Emilie | Saidi, Elamine | Larbanoix, Lionel | Stanicki, Dimitri | Nonclercq, Denis | Vander Elst, Luce | Laurent, Sophie | Muller, Robert N. | Burtea, Carmen
Article Type: Research Article
Abstract: The diagnosis of Alzheimer’s disease (AD) is a critical step in the management of patients. We have developed a non-invasive diagnosis tool based on magnetic resonance molecular imaging (MRMI) of amyloid-β peptide using ultra-small particles of iron oxide (USPIO) functionalized with a disulfide constrained cyclic heptapeptide (PHO) identified by phage display (USPIO-PHO). After previously demonstrating the optimal pharmacologic properties of USPIO-PHO and its capacity to cross the blood-brain barrier (BBB), the ability of USPIO-PHO to target amyloid plaques (AP) by MRMI has been validated in the present work on AD transgenic mice. The immunohistochemistry and immunofluorescent detection of USPIO-PHO on …brain sections collected after in vivo MRMI studies enabled its colocalization with AP, confirming the BBB passage and specific targeting. The AP targeting by USPIO-PHO has been moreover corroborated by the good correlation between the number of AP detected with anti-amyloid β antibody and Perls’-DAB staining. Finally, the crossing mechanism of USPIO-PHO through the BBB was elucidated, revealing the involvement of non-degradation pathway of caveolae, while the control contrast agent USPIO-PEG was not endocytosed by the human brain endothelial cells. Show more
Keywords: Alzheimer’s disease, amyloid-β peptide, blood-brain barrier, contrast agents, functionalized iron oxide nanoparticles, magnetic resonance imaging
DOI: 10.3233/JAD-170563
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1547-1565, 2017
Authors: Dardenne, Sophie | Delrieu, Julien | Sourdet, Sandrine | Cantet, Christelle | Andrieu, Sandrine | Mathiex-Fortunet, Hélène | Fougère, Bertrand | Vellas, Bruno
Article Type: Research Article
Abstract: Background: Subjective cognitive decline (SCD) may be a very early symptom of Alzheimer’s disease (AD) and may be associated with a cognitive decline in a cognitively normal population. The McNair and Kahn Scale was used to assess memory complaints in the GuidAge study. Objective: Our objectives were to examine if the McNair and Kahn Scale can predict cognitive decline and to screen which (if any) of the question(s) of this scale would better predict this cognitive decline. Methods: The GuidAge study was a phase III, multicenter, randomized, double blind, placebo-controlled study. Individuals aged 70 years and …older, without cognitive impairment (Clinical Dementia Rate (CDR = 0)) at baseline who had spontaneously reported SCD were included in this study. The 20-item version of the McNair and Kahn Scale was used to assess SCD and a standardized neuropsychological assessment was used to assess the cognitive status. Results: 1,307 patients with SCD and with CDR = 0 at baseline were included. During the 5 years of follow-up, 519 patients showed cognitive decline. Incidence of aggravation score of CDR was 13.40% person years (95% CI [12.24–14.56]). Results showed a significant relationship between the McNair and Kahn Scale score and decline in cognitive performance (HR 1.012; 95% CI [1.002–1.021]; p = 0.0156). Among the 20 items, 5 were statistically significant to predict cognitive decline after adjustment. Conclusion: SCD is a promising indicator of memory impairment. Our study found that using the McNair and Kahn scale can predict cognitive decline. A 5-item version of this scale could be used to screen patients in clinical practice and in clinical research. Show more
Keywords: Alzheimer’s disease, cognitive decline, memory complaint, preclinical stage, subjective cognitive complaint
DOI: 10.3233/JAD-170229
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1567-1578, 2017
Authors: Jang, Hyemin | Ye, Byoung Seok | Woo, Sookyoung | Kim, Sun Woo | Chin, Juhee | Choi, Seong Hye | Jeong, Jee Hyang | Yoon, Soo Jin | Yoon, Bora | Park, Kyung Won | Hong, Yun Jeong | Kim, Hee Jin | Lockhart, Samuel N. | Na, Duk L. | Seo, Sang Won
Article Type: Research Article
Abstract: Background: Patients with amnestic mild cognitive impairment (aMCI) have an increased risk of dementia. However, conversion rate varies. Therefore, predicting the dementia conversion in these patients is important. Objective: We aimed to develop a nomogram to predict dementia conversion in aMCI subjects using neuropsychological profiles. Methods: A total of 338 aMCI patients from two hospital-based cohorts were used in analysis. All patients were classified into 1) verbal, visual, or both, 2) early or late, and 3) single or multiple-domain aMCI according to the modality, severity of memory dysfunction, and multiplicity of involved cognitive domains, respectively. Patients …were followed up, and conversion to dementia within 3 years was defined as the primary outcome. Our patients were divided into a training data set and a validation data set. The associations of potential covariates with outcome were tested, and nomogram was constructed by logistic regression model. We also developed another model with APOE data, which included 242 patients. Results: In logistic regression models, both modalities compared with visual only (OR 4.44, 95% CI 1.83–10.75, p = 0.001), late compared to early (OR 2.59, 95% CI 1.17–5.72, p = 0.019), and multiple compared to single domain (OR 3.51, 95% CI 1.62–7.60, p = 0.002) aMCI were significantly associated with dementia conversion within 3 years. A nomogram incorporating these clinical variables was constructed on the training data set and validated on the validation data set. Both nomograms with and without APOE data showed good prediction performance (c-statistics ≥ 0.75). Conclusions: This study showed that several neuropsychological profiles of aMCI are significantly associated with imminent dementia conversion, and a nomogram incorporating these clinical subtypes is simple and useful to help to predict disease progression. Show more
Keywords: Alzheimer’s disease, amnestic mild cognitive impairment, nomogram, prediction model
DOI: 10.3233/JAD-170507
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1579-1587, 2017
Authors: Tuwaig, Miranda | Savard, Mélissa | Jutras, Benoît | Poirier, Judes | Collins, D. Louis | Rosa-Neto, Pedro | Fontaine, David | Breitner, John C.S. | for the PREVENT-AD Research Group
Article Type: Research Article
Abstract: Prevention of dementia due to Alzheimer’s disease (d/AD) requires interventions that slow the disease process prior to symptom onset. To develop such interventions, one needs metrics that assess pre-symptomatic disease progression. Familiar measures of progression include cerebrospinal fluid (CSF) biochemical and imaging analyses, as well as cognitive testing. Changes in the latter can sometimes be difficult to distinguish from effects of “normal” aging. A different approach involves testing of “central auditory processing” (CAP), which enables comprehension of auditory stimuli amidst a distracting background (e.g., conversation in a noisy bar or restaurant). Such comprehension is often impaired in d/AD. Similarly, effortful …or diminished auditory comprehension is sometimes reported by cognitively healthy elders, raising the possibility that CAP deficit may be a marker of pre-symptomatic AD. In 187 cognitively and physically healthy members of the aging, AD family history-positive PREVENT-AD cohort, we therefore evaluated whether CAP deficits were associated with known markers of AD neurodegeneration. Such markers included CSF tau concentrations and magnetic resonance imaging volumetric and cortical thickness measures in key AD-related regions. Adjusting for age, sex, education, pure-tone hearing, and APOE ɛ 4 status, we observed a persistent relationship between CAP scores and CSF tau levels, entorhinal and hippocampal cortex volumes, cortical thickness, and deficits in cognition (Repeatable Battery for Assessment of Neuropsychological Status total score, and several of its index scales). These cross-sectional observations suggest that CAP may serve as a novel metric for pre-symptomatic AD pathogenesis. They are therefore being followed up longitudinally with larger samples. Show more
Keywords: Biomarkers, central auditory processing disorder, cognitive function, pre-clinical Alzheimer’s disease, prevention, sensorineural assessment
DOI: 10.3233/JAD-170545
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1589-1600, 2017
Authors: Torrens-Burton, Anna | Basoudan, Nasreen | Bayer, Antony J. | Tales, Andrea
Article Type: Research Article
Abstract: This study examines the relationships between two measures of information processing speed associated with executive function (Trail Making Test and a computer-based visual search test), the perceived difficulty of the tasks, and perceived memory function (measured by the Memory Functioning Questionnaire) in older adults (aged 50+ y) with normal general health, cognition (Montreal Cognitive Assessment score of 26+), and mood. The participants were recruited from the community rather than through clinical services, and none had ever sought or received help from a health professional for a memory complaint or mental health problem. For both the trail making and the visual search …tests, mean information processing speed was not correlated significantly with perceived memory function. Some individuals did, however, reveal substantially slower information processing speeds (outliers) that may have clinical significance and indicate those who may benefit most from further assessment and follow up. For the trail making, but not the visual search task, higher levels of subjective memory dysfunction were associated with a greater perception of task difficulty. The relationship between actual information processing speed and perceived task difficulty also varied with respect to the task used. These findings highlight the importance of taking into account the type of task and metacognition factors when examining the integrity of information processing speed in older adults, particularly as this measure is now specifically cited as a key cognitive subdomain within the diagnostic framework for neurocognitive disorders. Show more
Keywords: Aging, information processing speed, metacognition, reaction time, subjective cognitive impairment
DOI: 10.3233/JAD-170599
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1601-1609, 2017
Authors: Piers, Ryan J. | Devlin, Kathryn N. | Ning, Boting | Liu, Yulin | Wasserman, Ben | Massaro, Joseph M. | Lamar, Melissa | Price, Catherine C. | Swenson, Rod | Davis, Randall | Penney, Dana L. | Au, Rhoda | Libon, David J.
Article Type: Research Article
Abstract: Background: Digital Clock Drawing Test (dCDT) technology enables the examination of detailed neurocognitive behavior as behavior unfolds in real time; a capability that cannot be obtained using a traditional pen and paper testing format. Objective: Parameters obtained from the dCDT were used to investigate neurocognitive constructs related to higher-order neurocognitive decision making and information processing speed. The current research sought to determine the effect of age as related to combined motor and non-motor components of drawing, and higher-order decision making latencies. Methods: A large group of stroke- and dementia- free Framingham Heart Study participants were administered …the dCDT to command and copy with hands set for “10 after 11 ”. Six age groups (age range 28–98) were constructed. Results: Differences between age groups were found for total time to completion, total pen stroke count, and higher-order decision making latencies in both command and copy test conditions. Conclusion: Longer age-related decision making latencies may reflect a greater need for working memory and increased self-monitoring in older subjects. These latency measures have potential to serve as neurocognitive biomarkers of Alzheimer’s disease and other insidious neurodegenerative disorders. Show more
Keywords: Boston Process Approach, cognition, digital clock drawing test, graphomotor decision making, normal aging
DOI: 10.3233/JAD-170444
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1611-1620, 2017
Authors: Kirsebom, Bjørn-Eivind | Espenes, Ragna | Waterloo, Knut | Hessen, Erik | Johnsen, Stein Harald | Bråthen, Geir | Aarsland, Dag | Fladby, Tormod
Article Type: Research Article
Abstract: Background: Cognitive assessment is essential in tracking disease progression in AD. Presently, cohorts including preclinical at-risk participants are recruited by different means, which may bias cognitive and clinical features. We compared recruitment strategies to levels of cognitive functioning. Objective: We investigate recruitment source biases in self-referred and memory clinic-referred patient cohorts to reveal potential differences in cognitive performance and demographics among at-risk participants. Methods: We included 431 participants 40–80 years old. Participants were classified as controls (n = 132) or symptom group (n = 299). The symptom group comprised of subjective cognitive decline (SCD, n = 163) and mild …cognitive impairment (MCI, n = 136). We compared cognitive performance and demographics in memory clinic-referrals (n = 86) to self-referred participants responding to advertisements and news bulletins (n = 179). Participants recruited by other means were excluded from analysis (n = 34). Results: At symptom group level, we found significant reductions in cognitive performance in memory clinic-referrals compared to self-referrals. However, here reductions were only found within the MCI group. We found no differences in cognitive performance due to recruitment within the SCD group. The MCI group was significantly impaired compared to controls on all measures. Significant reductions in learning, and executive functions were also found for the SCD group. Conclusion: Regardless of recruitment method, both the SCD and MCI groups showed reductions in cognitive performance compared to controls. We found differences in cognitive impairment for memory clinic-referrals compared to self-referrals only within the MCI group, SCD-cases being equally affected irrespective of referral type. Show more
Keywords: Alzheimer’s disease, cognitive dysfunction, mild cognitive impairment, patient recruitment, research subject recruitment, sampling studies, subjective cognitive decline
DOI: 10.3233/JAD-170385
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1621-1631, 2017
Authors: Cowan, Ronald L. | Beach, Paul A. | Atalla, Sebastian W. | Dietrich, Mary S. | Bruehl, Stephen P. | Deng, Jie | Wang, Jinjiao | Newhouse, Paul A. | Gore, John C. | Monroe, Todd B.
Article Type: Research Article
Abstract: Background: People with Alzheimer’s disease (AD) report pain less frequently and receive less pain medication than people without AD. Recent studies have begun to elucidate how pain may be altered in those with AD. However, potential sex differences in pain responsiveness have never been explored in these patients. It is unclear whether sex differences found in prior studies of healthy young and older individuals extend to people with AD. Objective: The purpose of this study was to examine sex differences in the psychophysical response to experimental thermal pain in people with AD. Methods: Cross-sectional analysis of …14 male and 14 female age-matched (≥65 years of age, median = 74) and AD severity-matched (Mini-Mental State Exam score <24, median = 16) communicative people who completed thermal psychophysics. Results: There was a statistically significant main effect of sex for both temperature and unpleasantness ratings that persisted after controlling for average and current pain (mixed-effects general liner model: temperature: p = 0.004, unpleasantness: p < 0.001). Females reported sensing mild pain and moderate pain percepts at markedly lower temperatures than did males (mild: Cohen ’s d = 0.72, p = 0.051, moderate: Cohen ’s d = 0.80, p = 0.036). By contrast, males rated mild and moderate thermal pain stimuli as more unpleasant than did females (mild: Cohen ’s d = 0.80, p = 0.072, moderate: Cohen ’s d = 1.32, p = 0.006). There were no statistically significant correlations of temperature with perceived unpleasantness for mild or moderate pain (rs = 0.29 and rs = 0.20 respectively, p > 0.05). Conclusions: Results suggest experimental pain-related sex differences persist in older adults with AD in a different manner than those previously demonstrated in cognitively intact older adults. These findings could potentially aid in developing targeted pain management approaches in this vulnerable population. Further studies are warranted to replicate the findings from this pilot work. Show more
Keywords: Alzheimer’s disease, dementia, pain, pain threshold, perception, sex differences
DOI: 10.3233/JAD-170532
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1633-1640, 2017
Authors: Dayon, Loïc | Wojcik, Jérôme | Núñez Galindo, Antonio | Corthésy, John | Cominetti, Ornella | Oikonomidi, Aikaterini | Henry, Hugues | Migliavacca, Eugenia | Bowman, Gene L. | Popp, Julius
Article Type: Research Article
Abstract: Background: Cerebrospinal fluid (CSF) biomarkers of the beta-amyloid and microtubule associated protein tau metabolism have proven the capacity to improve classification of subjects developing Alzheimer’s disease (AD). The blood plasma proteome was characterized to further elaborate upon the mechanisms involved and identify proteins that may improve classification of older adults developing an AD dementia. Objective: Identify and describe plasma protein expressions that best classify subjects with CSF-defined presence of AD pathology and cerebral amyloidosis. Methods: We performed a cross-sectional analysis of samples collected from community-dwelling elderly with (n = 72) or without (n = 48) cognitive impairment. CSF …Aβ1-42 , tau, and phosphorylated tau (P-tau181) were measured using ELISA, and mass spectrometry quantified the plasma proteomes. Presence of AD pathology was defined as CSF P-tau181/Aβ1-42 > 0.0779, and presence of amyloidosis was defined as CSF Aβ1-42 < 724 pg/mL. Results: Two hundred and forty-eight plasma proteins were quantified. Plasma proteins did not improve classification of the AD CSF biomarker profile in the whole sample. When the analysis was separately performed in the cognitively impaired individuals, the diagnosis accuracy of AD CSF profile was 88.9% with 19 plasma proteins included. Within the full cohort, there were 16 plasma proteins that improved diagnostic accuracy of cerebral amyloidosis to 92.4%. Conclusion: Plasma proteins improved classification accuracy of AD pathology in cognitively-impaired older adults and appeared representative of amyloid pathology. If confirmed, those candidates could serve as valuable blood biomarkers of the preclinical stages of AD or risk of developing AD. Show more
Keywords: Alzheimer’s disease, amyloid-β, amyloidosis, biomarker, dementia, protein, tau
DOI: 10.3233/JAD-170426
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1641-1652, 2017
Article Type: Other
DOI: 10.3233/JAD-179006
Citation: Journal of Alzheimer's Disease, vol. 60, no. 4, pp. 1653-1665, 2017
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl